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Abstract 
 
Many proteins are transported from the nucleus to the cytoplasm by the exportin CRM1, which 
recognizes cargo proteins through a leucine rich nuclear export signal (NES). This nuclear export 
process can be inhibited by several small molecules, both natural products and fully synthetic 
compounds. The structural basis for the inhibition of nuclear export by leptomycin (LMB) based on 
disruption of the protein/protein interaction between CRM1 and cargo proteins is discussed. The 
chemistry and inhibition of nucleocytoplasmic transport of leptomycin, anguinomycin and 
derivatives, goniothalamin, JBIR-02, valtrate, dihydrovaltrate, ACA, peumusolide A and several 
synthetic compounds is presented. Consequences for the design of nuclear export inhibitors is 
discussed, and the potential of these compounds as anticancer agents is evaluated. 
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Introduction 
 
Natural products often display the ability to selectively interact with biological targets from all 
major classes of biopolymers.[1] The successful application of these molecular interactions in living 
cells and organisms can result in the generation of desired phenotypes (so-called chemical 
genetics).[2] In contrast to classical genetic methods, the use of chemical interference allows for a 
spatial, temporal and dynamic control of phenotypes in living systems. [3] In addition, phenotypes 
can be generated that result from the inhibition of key pathways central to cellular viability. As 
many small molecule induced interferences are reversible or can be washed out, the resulting 
phenotypes can be transiently generated and studied. Over the last years, significant progress has 
been made in the inhibition of enzymes such as kinases, phosphatases and proteases and thus the 
shutdown of whole biochemical pathways.[4] This highlights the importance of selective chemical 
interference in biological systems by natural products. 
An interesting target for chemical interference is the control over the localization of proteins in 
living cells. [5-7] By achieving this goal, control over key biochemical pathways (i.e. by controlling 
the involved transporters) in a complementary manner to the classical enzyme inhibitors might be 
feasible.[8-10] In addition, by following this strategy, indirect control over non-enzyme biological 
modulators such as transcription factors of repressors, that are often regulated by nucleocytoplasmic 
shuttling,  can be achieved. [11, 12] The fundamental chemical challenge in achieving this goal 
consists of the nature of the protein transporters, which usually recognize larger peptide sequences 
of cargo proteins. For example, the exportin CRM1 recognizes a leucine rich terminal helix,[13-15] 
the so-called nuclear export signal (NES). [16] Thus for successful interference, small molecules 
should disrupt these protein/protein interactions and are thus required to target larger areas on a 
protein surface. Due to the difficulty of this subject, the breakdown of protein/protein complexes by 
small molecules is currently regarded as one of the general challenges in chemical biology. 
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In this review, I will summarize chemical approaches to control protein localization based on the 
inhibition of the CRM1 exportin by small molecules. The discovery and development of small 
molecule inhibitors of the protein/protein interaction of CRM1 with the NES of cargo proteins will 
be discussed and the molecular mode of action highlighted. Potential applications regarding the 
introduction of novel drugs in the clinic or towards new chemical tools in cell biology will be 
discussed. It should be pointed out that this review highlights recent developments in the field, and 
several excellent reviews have been published earlier [17, 18]. 
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Structural Background 
 
In 2009, two X-ray crystal structures of CRM1 interacting with snuportin 1 (SNUPN) have been 
published [19-21]. A model of the CRM1-SNUPN complex (Figure 1A) highlights the key 
interactions for molecular binding. The cargo protein SNUPN (in dark grey) is recognized by the 
exportin CRM1 (solid) through a nuclear export signal (NES, light grey helix, center). This 
hydrophobic helical appendage confers low affinity of the cargo protein to the exportin by binding 
into a hydrophobic grove. In particular, several hydrophobic side chains (Met1, Leu4, Leu8, Phe12, 
Val12) define the interaction between the NES and CRM1. In addition to this structural 
information, a seminal report from Kudo and colleagues demonstrated that the natural product 
leptomycin (LMB) is covalently alkylating the reactive Cys reside (528 in human CRM).[22, 23] 
This nucleophilic residue is located in  the upper end of this groove. Based on these data, we have 
developed molecular models detailing the atomistic interaction of the covalent binding of LMB to 
CRM1 (Figure 1B). [24] 
 
Figure 1. A: Model of CRM1 (solid) binding to cargo protein SNUPN (dark grey) via the NES 
(light grey, central).[19-21] B: Ball and stick model of LMB  binding to CRM1 (solid). [24] 
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A key feature of the proposed model is that the nuclear export signal of the cargo protein is replaced 
by LMB in mimicking the hydrophobic nature of the NES and binding to the same groove. As a 
consequence, the small molecule is thus shutting down this protein/protein interaction as the NES 
cannot bind anymore.[25, 26] The model of the LMB/CRM1 interaction is characterized by 
covalent linkage of CRM1 via the nucleophilic Cys residue 528 to the α,β-unsaturated lactone ring 
of CRM1. Based on modeling both outcomes of this attack, we proposed that the Re face of the 
Michael acceptor is attacked, although the calculated energy differences are rather small.[24] 
Starting from this covalent attachment, the remainder of the LMB molecule was modeled into the 
grove. It can be postulated that key methyl and ethyl groups in LMB mimic hydrophobic side 
chains of the NES: The ethyl group at C8 mimics Phe12, and the methyl groups at C14 and C16 
mimic Leu8 and Leu4 sidechains. The C10-C11 bond is crucial as by its synclinal arrangement 
results in a bend shape structure of LMB in the CRM1 binding groove. While LMB is in general 
very hydrophobic, an electrostatic interaction of the terminal carboxylate  with His558 or Lys 514 
residues can be postulated to increase binding.  
This model helps to explain the salient structural features of leptomycin in displacing the 
hydrophobic helical appendage NES from the protein cargo.[24] It also details how the cargo 
CRM1 protein/protein interaction can be disrupted by the covalent anchoring of LMB into the this 
hydrophobic groove of CRM1. In addition, this model provide structural information on how to 
modify the leptomycin skeleton to obtain smaller analogs which retain the affinity of disrupting the 
key protein/protein interaction and therefore inhibiting nuclear export. In the following sections, we 
will summarize our own research efforts starting from the LMB analogs anguinomycins C (2) and 
D (3), which have resulted in truncated yet active analog 6 and the target identification of 
goniothalamin (7).  
 
 
 
7 
 
Small Molecule Inhibitors of Nuclear Export 
 
The anguinomycins are potent antitumor agents[27, 28] active in the picomolar range that belong to 
the leptomycin family of natural products. The anguinomycins C and D have been reported to 
display selectivity against transformed cell lines, while only inducing growth arrest in normal 
cells.[27] This remarkable selectivity has been attributed to interference with pRB tumor 
suppressors, as reported  in the original isolation publication.[27] In the context of our program on 
the synthesis of biologically active natural products,[29-36] and intrigued by this remarkable 
selectivity, we have embarked on a total synthesis of these polyketides for further biological 
evaluation.[24, 37] In particular, we wanted to examine whether these compounds also constitute 
inhibitors of the CRM1 mediated nuclear export. 
We have synthesized anguinomycins C and D using Jacobsen Cr(III)-catalyzed hetero Diels-Alder 
reactions, Negishi cross couplings with stereoinversion to obtain the diene part, and Evans syn aldol 
methodology using the Seebach version of the Evans oxazolidinone. The fragments were merged by 
using a B-alkyl Suzuki Miyaura coupling, and, after deprotection, the totally synthetic 
anguinomycins C (2) and D (3) have been obtained. Comparison of spectra confirmed the identify 
of the synthetic material to the natural product and thus the absolute configuration of the natural 
product was established as well.[24, 37]  
Biological evaluation of the anguinomycins C and D by using immunostaining of the Rio2 kinase in 
HeLa cells demonstrated that anguinomycin C (2) starts to inhibit nucleopcytoplasmic transport at a 
concentration of 5 nM and a full block is observed at 10 nM concentration. Anguinomycin D (3) 
leads to full inhibtion at 10 nM concentration. These values demonstrate that anguinomycins C and 
D are indeed able to block the CRM1 mediated nuclear export pathway in concentrations which are 
comparable to LMB itself.[24, 37] 
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The aldehyde 4 was evaluated next in order to investigate the role of the lactone moiety. This 
compound was able to block nuclear export starting at 25 nM with a full shutdown observed at 50 
nM. These values confirm that a presence of a lactone is not mandatory for inhibition, and that the 
cyclic ester moiety in compounds 1-3 can be substituted by a linear aldehyde group. [24] 
Given the structural model developed for LMB binding discussed above (Figure 1B), we wondered 
whether substitution of the long polyketide tail by a simple hydrocarbon unit would be possible. In 
particular, we were interested whether the linear propionate part can be substituted by a structurally 
simpler terpene fragment, for example resulting from citronellal. Such natural product hybrids have 
been frequently described in the literature, and in the present case, a significant simplification of the 
synthetic endeavor needed for the preparation of the hybrid would be expected. Indeed, the 
anguinomycin/terpene hybrid 5 is able to block nucleocytoplasmic transport, albeit with loss of 
activity of one order of magnitude.[24] 
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Figure 2. Inhibitors of nucleocytoplasmic transport. 
 
A key discovery was observed when the truncated analog 6 was evaluated. This compound was 
obtained as a by-product (from protodepalladation in the fragment coupling) and lacks 13 C atoms 
of the polyketide chain and five stereogenic centers.[24] Surprisingly, this truncated analog 
displayed block of nuclear export above 25 nM, which represents approximately only a loss of a 
factor of two when compared to the parent, complex natural product. This result is truly remarkable, 
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as usually the bioactivity of natural products is closely related to their structural integrity, and 
cutting a natural product in two generally leads to a loss of activity. Concerning the question why 
evolution selected the complete anguinomycin D (3) or leptomycin (1), it should be pointed out that 
the producing organism was not selected based on its fitness in the CRM1-mediated nuclear export 
assay, but in much more complex ecological settings. The binding of compound 6 to CRM1 can 
again be rationalized by molecular modeling, and it can be argued that due to the covalent linkage, 
the truncated analog irreversibly binds to the exportin thus leading to shutdown of nuclear 
export.[24] 
Based on this key discovery, we wondered whether similar small unsaturated lactones of natural 
origin would also inhibit CRM1 via s similar mechanism. Goniothalamin (7) is the parent member 
of a class of similar styryl lactones isolated from various species of plants of the genus 
Goniothalamus (Annonaceae).[38] A broad manifold of biological activities has been described in 
many of the roughly 100 reports on this compound, a general cytoxicity against cancer cells, 
insects, fungi and others have been reported (for recent studies, see refs. [39-43]) In all reports, the 
exact mechanism of action and the target(s) of goniothalamin remained unclear. We have developed 
a new eight step synthetic route to goniothalamin (7) and have evaluated this material in the CRM1-
mediated nuclear export of Rio2 assay.[44] Confirming our initial hypothesis, goniothalamin (7) 
was indeed demonstrated to be an inhibitor of nucleocytoplasmic transport, and inhibition was 
observed above 500 nM concentration.[44] As goniothalamin has been reported to display 
cytotoxivity in breast cancer cells with IC50 value of ca. 1.5 µM leading to growth arrest and 
apoptosis, it can be hypothesized that these effects are based on a block of CRM1-mediated nuclear 
export at this concentration. This recent study[44] thus enlarged the arsenal of natural products that 
might be able to interfere and to block the CRM1 mediated nuclear export pathway to other natural 
products. It might also be tempting to speculate whether compounds endogenous in humans might 
be able to interfere with this key pathway in human cells. 
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Figure 3: Natural products and derivatives targeting nuclear export. 
 
Several other natural products and derivatives have been reported to block nuclear export of cargo 
proteins. JBIR-02 (8) constitutes a piericidin derivative isolated from a Streptomyces strain in the 
context of screening for small molecule modulators of arrestin translocation.[45] Arrestins are 
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scaffolding proteins that are involved in the internalization and desensitization of G-protein coupled 
receptors. JBIR-02 inhibited nuclear export of a fluorescent fusion protein of β-arrestin at a 
concentration of 20 µΜ. Interestingly, the corresponding hydroxyperidine tautomer with an 
additional CH3O group in the 2 position was not active up to 80 µΜ concentration, and displayed 
cytotoxicity at elevated concentrations. The authors postulated that JBIR-02 (8) operates in a 
similar manner as LMB in binding to the same hydrophobic grove as discussed earlier.[45]  
Valtrate (9), originally isolated by Thies [46] was obtained during a screening of 200 extracts from 
medicinal plants for nuclear export inhibitors.[47] This compound inhibited Rev export in the 
fission yeast Schizosaccharomyces pombe at a concentration of 3 µg/mL. By using a biotinylated 
LMB probe, the authors could demonstrate that 9 operates in a mode of action similar to LMB and 
it was demonstrated that the epoxide can be opened by a protected Cys derivative to give the 
thiolate adduct, which might be of relevance as a model for CRM1 inhibition. Murakami and 
coworkers then later developed an interesting synthetic route towards 5,6-dihydrovaltrate (10), 
which was shown to display only a slightly decreased activity when compared to 9.[48] 
Nonetheless, the authors noted the limited supply of natural 9 (0.006 % isolated yield) as a reason 
for the total synthesis of this complex iridoid derivative 10.[48] 
A similar screen for Rev export inhibitors by the same group resulting in the isolation and 
characterization of 1’-acetoxychavicol acetate (ACA, 11) from Alpinia galanga. [49] This 
compound was shown to operate in a similar manner as LMB and was active at 4.7 µM 
concentrationin the fission yeast assay. It demonstrated by the synthesis of analogs that both Ac 
groups are necessary as is the absolute configuration.[49] A follow-up study proposed that the 
quinone methide intermediate 12 would be the biologically active compound, and prepared several 
compounds allowing to probe the different rates of Ac hydrolysis and elimination. [50] These 
efforts led to the identifaction of the difluoroanalog 13, which showed better activity, both in the 
fission yeast assay (1.4 µM) and in the immunostaining assay in HeLa cells (130 nM).[50]  
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Peumusolide A (14) was obtained as a NES non-antagonistic inhibitor from the South American 
medicinal plant Peumus boldus.[51] This compound 14 has been shown to inhibit the nuclear export 
of the MAPK/ERK kinase at low micromolar values. The authors suggest that the mode of action is 
not related to the nuclear export signal (NES), as the compound was found to retain activity when 
cells were pretreated with a biotinylated probe of LMB. The exact mode of action of this compound 
needs to be investigated further.[51] 
Another NES non-antagonistic inhibitor, the fatty acid derivative 15, was reported by Murakami 
and co-workers.[52] Synthetic studies aimed at the investigation of structure/activity relationships 
demonstrated that either truncated, saturated, or small analogs were less active supporting the 
notion that a cooperation of the carboxylate, the OH group and the diene in exact distance is 
required for biological activity. 
In addition to these natural products and derivatives, several synthetic compounds interfering with 
nuclear export have been identified. A chemical genetic screen directed towards the identification 
of inhibitors of the FOXO1a nuclear export yielded several interesting compounds.[53] From 18000 
compounds screened, 42 compounds were identified as export inhibitors. In order to differentiate 
between general nuclear export inhibitors and more specific inhibitors targeting the 
PI3K/Akt/FOXO1a signaling pathway, these hits were evaluated in the classical Rev export 
inhibition assay. Among these compounds, 19 Rev export inhibitors were obtained that were shown 
to interact with CRM1 mediated nuclear export. A survey of these 19 compounds established that 
eight compounds contained α,β-unsaturated ketones such as 16 or maleimides such as 17, three 
contained electrophilic C atoms with good leaving groups (exemplified by 18). Several alkynes 
such as 19 were obtained as well as other compounds that do not reveal reactive groups at first 
sight. A closer investigation of their mode of action would be warranted, although contaminations 
with reactive compounds could also be plausible.[53] 
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Figure 4. Synthetic inhibitors of nuclear export. 
Vandamme and coworkers reported in 2002 the triazole 20 as a low molecular weight inhibitor 
blocking the CRM1 mediated nuclear export.[54] In a subsequent study, the same group showed 
that the originally reported structure was erroneous, and that instead the 3-substituted triazole 21 
was the active compound.[55] A structure activity study revealed key points for activity, and the 
presence of the α,β-unsaturated ester was found necessary, which is in line with earlier studies on 
covalent inhibitors. Based on these investigations, tetrazole 22 was identified as most potent 
compound evaluated.[55] A similar set of α,β-unsaturated amides was identified by a Novartis 
group in 2009.[56] A sophisticated high content screen for inhibitors of HDAC nuclear export of > 
100000 compounds and 1 billion cells resulted in a proposed hit structure. Closer investigation of 
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the hit compound revealed that an impurity caused the positive signal, and it was shown that α,β-
unsaturated diamide 23 was the active compound. This compound resulted in a 2.2 nM 
concentration for successful inhibition of HDAC5 nuclear export. 
 
Conclusion 
 
The many disclosures of both natural products and fully synthetic compounds used as nuclear 
export inhibitors over the last couple of years is a testimony to their power in controlling a key 
pathway in eukaryotic cells. In addition, their use for chemical interference, resulting in phenotypes 
that are difficult to obtain by traditional genetics, can be highlighted. The potential of these 
compounds to treat diseases such as cancer will certainly be evaluated in the future. 
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